Novel Therapies for Glioblastoma

Purpose of Review Glioblastoma (GBM) is the most common malignant primary brain tumor, and the available treatment options are limited. This article reviews the recent preclinical and clinical investigations that seek to expand the repertoire of effective medical and radiotherapy options for GBM. Re...

Full description

Saved in:
Bibliographic Details
Published in:Current neurology and neuroscience reports 2020-07, Vol.20 (7), p.19-19, Article 19
Main Authors: Liu, Elisa K., Sulman, Erik P., Wen, Patrick Y., Kurz, Sylvia C.
Format: Article
Language:English
Subjects:
Brain cancer
Brain Neoplasms - therapy
Brain tumors
Clinical trials
Glioblastoma
Glioblastoma - therapy
Humans
Immunotherapy
Medicine
Medicine & Public Health
Neuro-Oncology (P. Wen
Neurology
Neurosciences
Radiation therapy
Section Editor
Topical Collection on Neuro-Oncology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of Review Glioblastoma (GBM) is the most common malignant primary brain tumor, and the available treatment options are limited. This article reviews the recent preclinical and clinical investigations that seek to expand the repertoire of effective medical and radiotherapy options for GBM. Recent Findings Recent phase III trials evaluating checkpoint inhibition did not result in significant survival benefit. Select vaccine strategies have yielded promising results in early phase clinical studies and warrant further validation. Various targeted therapies are being explored but have yet to see breakthrough results. In addition, novel radiotherapy approaches are in development to maximize safe dose delivery. Summary A multitude of preclinical and clinical studies in GBM explore promising immunotherapies, targeted agents, and novel radiation modalities. Recent phase III trial failures have once more highlighted the profound tumor heterogeneity and diverse resistance mechanisms of glioblastoma. This calls for the development of biomarker-driven and personalized treatment approaches.
ISSN:1528-4042
1534-6293
DOI:10.1007/s11910-020-01042-6